Diabetes Mellitus
Conditions
Interventions
This is a randomized, prospective, blind clinical trial, with an analytical and quantitative approach. Patients with type 2 diabetes mellitus, users of Hagedorn neutral and/or regular protamine insuli
Sponsors
Universidade Regional do Noroeste do Estado do Rio Grande do Sul - UNIJUI
Universidade Regional do Noroeste do Estado do Rio Grande do Sul - UNIJUI
Eligibility
Age
35 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes mellitus (DM2); who use Hagedorn's neutral protamine insulin (NPH) and/or regular insulin; who collect these medicines from the Municipal Pharmacy of Ijuí; between 35 and 70 years old; with autonomy to use medications and apply insulin; who do not need a caregiver; with changes in capillary blood glucose previously measured in a pharmacist's office (blood glucose levels above 180 mg/dL at any time of the day).
Exclusion criteria
Exclusion criteria: Patients with type 1 diabetes mellitus (DM1); pregnant women; under 35 years old and over 70 years old; with circumstances that do not allow filling out the questionnaires (inability to speak, see or hear); those with a medical diagnosis of cognitive impairment; those that are banned; those who do not agree to participate in the research; those who do not sign the Free and Informed Consent Form (TCLE).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find a reduction in glycated hemoglobin, found in the method Fajriansyah et al. 2020, of at least 0.5%, when comparing the patient himself from the beginning to the end of the six months of intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find an average reduction in glycemia between the groups, found in the method of Javaid et al. 2019, of at least 1.18 mg/dL. | — |
Countries
Brazil
Contacts
Public ContactAndressa Diel
Universidade Regional do Noroeste do Estado do Rio Grande do Sul - UNIJUI
Outcome results
None listed